| scholarly article | Q13442814 |
| P2093 | author name string | Carol A Lange | |
| Benjamin E Rich | |||
| David J Burns | |||
| Sara A Hurvitz | |||
| Yao Huang | |||
| Leo T Furcht | |||
| Brian F Sullivan | |||
| Abhijit Dandapat | |||
| Ian A MacNeil | |||
| Lance G Laing | |||
| Sajjad M Soltani | |||
| Samantha Myhre | |||
| P2860 | cites work | The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 |
| Activating HER2 mutations in HER2 gene amplification negative breast cancer | Q27851987 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects | Q28678663 | ||
| Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array | Q33251283 | ||
| Discovery and validation of breast cancer subtypes | Q33257139 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies | Q33593016 | ||
| An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation | Q33733313 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications | Q34223494 | ||
| Targeting HER2 in other tumor types | Q34346131 | ||
| Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping | Q34436356 | ||
| Label-Free Receptor Assays | Q34473007 | ||
| Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase | Q34720797 | ||
| Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study | Q35078787 | ||
| The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease | Q35201328 | ||
| Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains | Q35533503 | ||
| HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive | Q35812023 | ||
| Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer | Q35895370 | ||
| Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. | Q36221780 | ||
| Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells | Q36311216 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. | Q37523202 | ||
| Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation. | Q37568043 | ||
| Bistability in one equation or fewer | Q38077718 | ||
| HER2 testing: current status and future directions. | Q38147681 | ||
| Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer | Q38463900 | ||
| Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer | Q38888022 | ||
| Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. | Q39742222 | ||
| Serum-free solutions for cryopreservation of cells | Q40078788 | ||
| Strategies for cell permeabilization and fixation in detecting surface and intracellular antigens | Q40844876 | ||
| Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy | Q42025768 | ||
| Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers | Q42457867 | ||
| HER3 overexpression and survival in solid tumors: a meta-analysis | Q43659959 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study. | Q44383595 | ||
| High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines | Q46452729 | ||
| Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer | Q46701849 | ||
| Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies | Q48205560 | ||
| HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. | Q50949577 | ||
| Evaluation of HER2/neu Status by Immunohistochemistry Using Computer-Based Image Analysis and Correlation With Gene Amplification by Fluorescence In Situ Hybridization Assay: A 10-Year Experience and Impact of Test Standardization on Concordance Rat | Q55054330 | ||
| Reconstruction of human mammary tissues in a mouse model | Q80092812 | ||
| HER2 status and benefit from adjuvant trastuzumab in breast cancer | Q80959592 | ||
| Prognostic relevance of gene amplifications and coamplifications in breast cancer | Q81085059 | ||
| Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients | Q81414756 | ||
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 78577-78590 | |
| P577 | publication date | 2016-10-05 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity | |
| P478 | volume | 7 |
| Q89612527 | New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified | cites work | P2860 |
Search more.